Interstitial Lung Disease Global Market Report 2024

The global interstitial lung disease market has grown strongly in recent years. It will grow from $1.83 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to awareness and diagnosis improvement, immune system modulation therapies, respiratory rehabilitation programs, multidisciplinary care teams.

The global interstitial lung disease market is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to precision medicine, novel drug development, regenerative medicine, telehealth and remote monitoring. Major trends in the forecast period include advancements in imaging technology, ai in imaging, fibrosis subtype differentiation, supportive care services.

The expansion in the prevalence of allergic conditions is anticipated to be a driving force behind the growth of the interstitial lung disease market in the future. Allergic conditions occur when the immune system reacts excessively to allergens, often harmless substances. These allergic reactions can lead to interstitial lung disease (ILD), specifically hypersensitivity pneumonitis, which is triggered by an allergic response within the body. For instance, as of January 2023, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported that in 2021, over one-third of American adults and more than one-fourth of American children experienced seasonal allergies, eczema, or food allergies. Additionally, severe allergic reactions to food, known as anaphylaxis, were estimated to result in 90,000 emergency room visits in the United States annually. Hence, the growing prevalence of allergic conditions is a significant driver of the interstitial lung disease market's growth.

The increasing incidence of autoimmune ailments is set to propel the expansion of the interstitial lung disease market in the foreseeable future. Autoimmune ailments refer to medical conditions where the immune system mistakenly targets the body's healthy tissues and cells. The rise in autoimmune ailment cases plays a crucial role in the interstitial lung disease market by augmenting the demand for healthcare services related to ILD, spurring research and development initiatives, and fostering advancements in treatments and patient care. For instance, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research center, projected that the global cases of rheumatoid arthritis would increase from around 17.6 million in 2020 to approximately 31.7 million by 2050. This substantial rise in cases over the coming decades underscores the growing incidence of autoimmune ailments. Consequently, the increasing prevalence of autoimmune ailments is a key driver of the interstitial lung disease market's growth.

The growth of the interstitial lung disease market is hindered by delayed diagnoses during the forecast period. Delayed diagnosis of interstitial lung disease (ILD) poses significant challenges to patients as it raises the risk of complications and has psychosocial impacts, ultimately leading to increased healthcare costs. For example, in 2021, the British Thoracic Society, a UK-based charitable organization, reported substantial delays between the onset of ILD symptoms and the actual diagnosis, with approximately 40% of patients enduring waiting periods exceeding two years before receiving a formal diagnosis. Consequently, delayed diagnosis has impeded the progress of the interstitial lung disease market.

Major companies operating in the interstitial lung disease market are committed to developing innovative drugs to provide effective treatment options and maintain their market standing. The development of new drugs holds the potential to improve treatment outcomes for patients with lung-related conditions. For instance, in April 2021, United Therapeutics, a US-based biotechnology company, introduced Tyvaso, a medication designed to enhance exercise capacity in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso is a sterile form of the prostacyclin-mimicking drug treprostinil, specifically designed for oral inhalation using the Tyvaso inhalation system.

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. This strategic acquisition is aimed at strengthening Merck & Co.'s immunology drug pipeline as it faces the looming loss of exclusivity for some of its top-selling products in the coming years. Prometheus Biosciences Inc., a US-based biotechnology company, specializes in developing therapeutic and complementary diagnostic products for the management of immune-mediated disorders, including interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD).

Major players in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.

North America was the largest region in the interstitial lung disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the interstitial lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of drugs used in the treatment of interstitial lung disease include oral corticosteroids, immunosuppressive medications, anti-fibrotic drugs, and others. Interstitial pneumonia, also referred to as non-infectious interstitial pneumonia, is a specific type of interstitial lung disease (ILD) that affects the interstitium, the tissue supporting the air sacs (alveoli) in the lungs. These drugs are indicated for the treatment of various ILD conditions, including interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis in both adults and children. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

This report provides interstitial lung disease market statistics, including interstitial lung disease industry global market size, regional shares, competitors with an interstitial lung disease market share, detailed interstitial lung disease market segments, market trends and opportunities and any further data you may need to thrive in the interstitial lung disease industry. This interstitial lung disease market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.